BR112021020924A2 - Uso de um anticorpo anti-cd19 para tratar doença autoimune - Google Patents

Uso de um anticorpo anti-cd19 para tratar doença autoimune

Info

Publication number
BR112021020924A2
BR112021020924A2 BR112021020924A BR112021020924A BR112021020924A2 BR 112021020924 A2 BR112021020924 A2 BR 112021020924A2 BR 112021020924 A BR112021020924 A BR 112021020924A BR 112021020924 A BR112021020924 A BR 112021020924A BR 112021020924 A2 BR112021020924 A2 BR 112021020924A2
Authority
BR
Brazil
Prior art keywords
antibody
autoimmune disease
treat autoimmune
treat
vib551
Prior art date
Application number
BR112021020924A
Other languages
English (en)
Portuguese (pt)
Inventor
Eliezer Katz
Jorn Drappa
Kathleen Mckeever
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of BR112021020924A2 publication Critical patent/BR112021020924A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021020924A 2019-04-24 2020-04-23 Uso de um anticorpo anti-cd19 para tratar doença autoimune BR112021020924A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US201962858495P 2019-06-07 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
BR112021020924A2 true BR112021020924A2 (pt) 2022-04-19

Family

ID=72940915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020924A BR112021020924A2 (pt) 2019-04-24 2020-04-23 Uso de um anticorpo anti-cd19 para tratar doença autoimune

Country Status (12)

Country Link
US (1) US20220204617A1 (https=)
EP (1) EP3959241A4 (https=)
JP (2) JP7779738B2 (https=)
KR (1) KR20220004113A (https=)
CN (1) CN113939532A (https=)
AU (1) AU2020263418A1 (https=)
BR (1) BR112021020924A2 (https=)
CA (1) CA3136487A1 (https=)
IL (1) IL287385A (https=)
MX (1) MX2021012870A (https=)
SG (1) SG11202111429UA (https=)
WO (1) WO2020219743A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of anti-CD19 antibody to treat myasthenia gravis
KR20250044695A (ko) 2022-07-27 2025-04-01 비엘라 바이오, 인크. 이네빌리주맙 및 지속적인 b-세포 고갈을 위한 이의 사용 방법
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
SI2066349T1 (sl) * 2006-09-08 2012-08-31 Medimmune Llc Humanizirana anti-cd19 protitelesa in njihova uporaba v zdravljenju tumorjev, transplantacijah in avtoimunih boleznih
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
CN104640560A (zh) * 2012-03-12 2015-05-20 米迪缪尼有限公司 用抗-cd19抗体治疗多发性硬化症
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Also Published As

Publication number Publication date
MX2021012870A (es) 2022-01-18
WO2020219743A2 (en) 2020-10-29
US20220204617A1 (en) 2022-06-30
EP3959241A4 (en) 2023-01-25
JP2022529743A (ja) 2022-06-23
IL287385A (en) 2021-12-01
EP3959241A2 (en) 2022-03-02
SG11202111429UA (en) 2021-11-29
JP7779738B2 (ja) 2025-12-03
JP2025157413A (ja) 2025-10-15
CA3136487A1 (en) 2020-10-29
CN113939532A (zh) 2022-01-14
KR20220004113A (ko) 2022-01-11
AU2020263418A1 (en) 2021-11-11
WO2020219743A3 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
BR112021020924A2 (pt) Uso de um anticorpo anti-cd19 para tratar doença autoimune
CU20200090A7 (es) Anticuerpos frente a entpd2 y terapias de combinación
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
CR20220479A (es) Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EA200970556A1 (ru) Моноклональные антитела против angptl3
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
AR114112A1 (es) Anticuerpos de glipicano 3 y conjugados de los mismos
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
UY38244A (es) AGENTES ENLAZANTES DE PSMA y SUS USOS
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
BR112018002386A8 (pt) Anticorpo contra glypican-3 e aplicação do mesmo
DOP2014000052A (es) Anticuerpo anti-alfabeta tcr
CL2021000146A1 (es) Anticuerpos humanizados contra psma
BR112019001206A2 (pt) anticorpos monoclonais humanizados que visam ve-ptp (hptp-ss)
EA202192130A1 (ru) Специфичные к ltbp-комплексу ингибиторы tgf и их применение
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
UY37683A (es) Anticuerpo monoclonal anti-pd-l1 monoclonal
AR120093A1 (es) Anticuerpos anti-ceacam y usos de los mismos
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
CO2022010204A2 (es) Anticuerpos contra la integrina alfa 11 beta 1
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VIELA BIO, INC. (US)